Abdominal Aortic Aneurysm Market Insights, Epidemiology and Market Forecast-2030

Albany, NY -- (SBWire) -- 03/02/2020 --Abdominal Aortic Aneurysm Market Insights, Epidemiology and Market Forecast-2030

(Albany, US) DelveInsight launched a new report on Abdominal Aortic Aneurysm Market Insights, Epidemiology and Market Forecast-2030

Some of the key facts of the report
1. Abdominal Aortic Aneurysm affects approximately 2% to 8% of the population older than 60 years.
2. Abdominal Aortic Aneurysm prevalence increases rapidly in men after age 55 years and in women after age 70 years.
3. Abdominal Aortic Aneurysm is the most commonly due to degeneration from arteriosclerosis. It comprises 65% of all aortic aneurysms; 90% occur below the renal arteries.
4. The studies have shown an increased Abdominal Aortic Aneurysm incidence worldwide, ranging from 4.2% to 11% per year.
5. Every year, 200,000 people in the US are diagnosed with an abdominal aortic aneurysm.

Key benefits of the report
1. Abdominal Aortic Aneurysm market report covers a descriptive overview and comprehensive insight of the Abdominal Aortic Aneurysm epidemiology and Abdominal Aortic Aneurysm market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Abdominal Aortic Aneurysm market report provides insights on the current and emerging therapies.
3. Abdominal Aortic Aneurysm market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Abdominal Aortic Aneurysm market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Abdominal Aortic Aneurysm market.

Request for sample pages

"Abdominal Aortic Aneurysm is more common in men than in women."

The golden standard of Abdominal Aortic Aneurysm treatments is invasive interventions either with open surgical repair (OS) or endovascular aneurysm repair (EVAR). The concept of medical treatment is to prevent the disease from rupture and avoid surgical treatment by preventing aneurysm enlargement or even reducing aneurysm size. Matrix metalloproteinases (MMP) are structurally related metalloendopeptidases that can degrade the extracellular matrix, and is thought to play essential roles. There are many proposed pharmacological treatments, including ?-blockers, angiotensin-converting enzyme inhibitor (ACE inhibitors), angiotensin-receptor blocker (ARB), statins, macrolides and, doxycycline, an inhibitor of the MMP. Specific treatment is based on the age, overall health, medical history, extent of the disease, signs and symptoms, tolerance of specific medications, procedures, or therapies.

Unfortunately, no pharmacotherapy has been realized despite considerable effort, and several challenges need to be addressed. First, it is possible that appropriate drug targets in Human Abdominal Aortic Aneurysm have not been identified. Indeed, many animal studies have assessed the effects of interventions in limiting Abdominal Aortic Aneurysm development rather than the effects on pre-established Abdominal Aortic Aneurysm. Also, the experimental opportunities for analyzing human Abdominal Aortic Aneurysm specimens have decreased in recent years. Continued efforts, including the appropriate use and interpretation of animal models, and full utilization of human samples are essential to gain a better understanding of Human Abdominal Aortic Aneurysm pathophysiology and pathogenesis. Second, it is essential for pharmacotherapy to be sufficiently concentrated at the site. Third, there is a possibility that the heterogeneity of human Abdominal Aortic Aneurysm might not be fully appreciated or taken into account when testing therapeutic agents since patients with Abdominal Aortic Aneurysm are heterogeneous in terms of their characteristics, clinical history, and genetic background.
Therefore, it may be better to stratify Abdominal Aortic Aneurysm patients according to the predominant biological activities; towards this end, identification of biomarkers accurately reflect the biological activity. If researchers can optimize therapeutic regimens for individual patients using biomarkers (personalized medicine), the patient may be able to achieve more effective outcomes with pharmacologic therapy and prevent or slow Abdominal Aortic Aneurysm progression. The companies are currently working toward this indication to meet the needs of the current Abdominal Aortic Aneurysm market, and subsequently redress the current issues. Pipeline drugs in clinical development are designed to address this unmet need in the Abdominal Aortic Aneurysm treatment. The other factors that shall further expedite the growth of the Abdominal Aortic Aneurysm market include increasing morbidity rate and increasing awareness about available treatments during the forecast period (2020–2030). A better understanding of disease pathogenesis will also contribute to the development of novel Abdominal Aortic Aneurysm therapeutics.

The launch of the emerging therapies is expected to significantly impact Abdominal Aortic Aneurysm treatment scenario in the upcoming years:-
Drugs covered
1. Metformin Glucophage
2. Ticagrelor
And many others

The key players in Abdominal Aortic Aneurysm market are:

1. Merck Serono
2. AstraZeneca
And many others

Table of contents
1. Report Introduction
2. Executive Summary
3. SWOT Analysis
4. Abdominal Aortic Aneurysm Market Overview at a Glance
5. Abdominal Aortic Aneurysm Disease Background and Overview
6. Abdominal Aortic Aneurysm Epidemiology and Patient Population
7. Abdominal Aortic Aneurysm Country- Wise Epidemiology
7.1. United States
7.2. EU-5
7.2.1. Germany
7.2.2. France
7.2.3. Italy
7.2.4. Spain
7.2.5. United Kingdom
7.3. Japan
8. Abdominal Aortic Aneurysm Treatment & Medical Practices
9. Patient Journey
10. Key Abdominal Aortic Aneurysm Emerging Therapies
10.1. Metformin Glucophage: Merck Serono
10.2. Ticagrelor: AstraZeneca
11. Attribute Analysis
12. Abdominal Aortic Aneurysm Market Size
13. 7MM Abdominal Aortic Aneurysm Country-Wise Market Analysis
14.1. United States
14.2. Germany
14.3. France
14.4. United Kingdom
14.5. Spain
14.6. Italy
14.7. Japan
15. Market Access and Reimbursement
16. Market Drivers
17. Market Barriers
18. Appendix
19. Abdominal Aortic Aneurysm Report Methodology
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:
Shruti Thakur
info@delveinsight.com
+919650213330
SOURCE DelveInsight